Free Trial

Diaceutics (DXRX) Competitors

Diaceutics logo
GBX 139.89 +2.39 (+1.74%)
As of 10:30 AM Eastern

DXRX vs. AGL, YGEN, ABDX, PRM, GDR, GENI, VRCI, DMTR, LLAI, and LLA

Should you be buying Diaceutics stock or one of its competitors? The main competitors of Diaceutics include ANGLE (AGL), Yourgene Health (YGEN), Abingdon Health (ABDX), Proteome Sciences (PRM), genedrive (GDR), GENinCode (GENI), Verici Dx (VRCI), Deepmatter Group (DMTR), LungLife AI (LLAI), and LLA.L,0P0001T9GN,0 (LLA). These companies are all part of the "diagnostics & research" industry.

Diaceutics vs. Its Competitors

Diaceutics (LON:DXRX) and ANGLE (LON:AGL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

Diaceutics has higher revenue and earnings than ANGLE. Diaceutics is trading at a lower price-to-earnings ratio than ANGLE, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Diaceutics£26.08M4.53-£2.84M-£3.37-41.49
ANGLE£2.44M8.25-£21.76M-£6.76-0.92

Diaceutics has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500. Comparatively, ANGLE has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500.

Diaceutics currently has a consensus price target of GBX 175, suggesting a potential upside of 25.10%. ANGLE has a consensus price target of GBX 40, suggesting a potential upside of 540.00%. Given ANGLE's higher possible upside, analysts clearly believe ANGLE is more favorable than Diaceutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Diaceutics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
ANGLE
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Diaceutics has a net margin of -10.90% compared to ANGLE's net margin of -890.91%. Diaceutics' return on equity of -7.15% beat ANGLE's return on equity.

Company Net Margins Return on Equity Return on Assets
Diaceutics-10.90% -7.15% -6.06%
ANGLE -890.91%-76.01%-29.89%

52.4% of Diaceutics shares are owned by institutional investors. Comparatively, 18.8% of ANGLE shares are owned by institutional investors. 34.3% of Diaceutics shares are owned by insiders. Comparatively, 16.2% of ANGLE shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Diaceutics' average media sentiment score of 0.00 equaled ANGLE'saverage media sentiment score.

Company Overall Sentiment
Diaceutics Neutral
ANGLE Neutral

Summary

Diaceutics beats ANGLE on 10 of the 13 factors compared between the two stocks.

Get Diaceutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DXRX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DXRX vs. The Competition

MetricDiaceuticsDiagnostics & Research IndustryMedical SectorLON Exchange
Market Cap£118.06M£1.15B£5.74B£3.17B
Dividend YieldN/A5.44%3.95%5.04%
P/E Ratio-41.492.2831.37169.17
Price / Sales4.53473.82430.58464,912.68
Price / Cash3.1211.4237.7527.93
Price / Book3.052.5710.596.93
Net Income-£2.84M£334.07B£3.27B£5.89B
7 Day Performance1.89%1.21%0.91%0.31%
1 Month Performance3.62%8.69%5.56%50.06%
1 Year Performance5.71%3.17%50.64%154.03%

Diaceutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DXRX
Diaceutics
N/AGBX 139.89
+1.7%
GBX 175
+25.1%
+5.3%£118.06M£26.08M-41.49151
AGL
ANGLE
1.7256 of 5 stars
GBX 6.25
+4.2%
GBX 40
+540.0%
-51.7%£20.14M£2.44M-0.92650Negative News
YGEN
Yourgene Health
N/AN/AN/AN/A£16.43M£29.67M-51.50253
ABDX
Abingdon Health
N/AGBX 6
-4.0%
N/A-45.0%£11.62M£3.84M-14.5984Gap Down
PRM
Proteome Sciences
N/AGBX 2.93
-2.5%
N/A-14.7%£8.63M£10.88B-2.12240Gap Down
GDR
genedrive
N/AGBX 0.80
flat
N/A-69.7%£4.54M£1.50M-0.2243Gap Up
High Trading Volume
GENI
GENinCode
N/AGBX 1.43
+1.8%
N/A-81.3%£2.53M£2.67M-0.422,300
VRCI
Verici Dx
N/AGBX 0.51
-3.8%
N/A-92.5%£1.53M£5.91M-0.2919Gap Down
DMTR
Deepmatter Group
N/AN/AN/AN/A£1.33M£1.04M-0.11N/AGap Down
LLAI
LungLife AI
N/AGBX 3.50
-17.6%
N/A-75.0%£1.16M£33.87K-0.2815Gap Down
High Trading Volume
LLA
LLA.L,0P0001T9GN,0
N/AN/AN/AN/A£0.00N/A-25.0015Gap Down
High Trading Volume

Related Companies and Tools


This page (LON:DXRX) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners